Data Insights

IPH-6501 by Innate Pharma for Marginal Zone B-cell Lymphoma: Likelihood of Approval

IPH-6501 is under clinical development by Innate Pharma and currently in Phase II for Marginal Zone B-cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - IPH-6501 in Marginal Zone B-cell Lymphoma

Data Insights

IPH-6501 by Innate Pharma for Thymic Carcinoma: Likelihood of Approval

IPH-6501 is under clinical development by Innate Pharma and currently in Phase II for Thymic Carcinoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - IPH-6501 in Thymic Carcinoma

Data Insights

IPH-6501 by Innate Pharma for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval

IPH-6501 is under clinical development by Innate Pharma and currently in Phase II for B-Cell Non-Hodgkin Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - IPH-6501 in B-Cell Non-Hodgkin Lymphoma

Data Insights

IPH-6501 by Innate Pharma for Follicular Lymphoma: Likelihood of Approval

IPH-6501 is under clinical development by Innate Pharma and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - IPH-6501 in Follicular Lymphoma

Data Insights

IPH-6501 by Innate Pharma for Mantle Cell Lymphoma: Likelihood of Approval

IPH-6501 is under clinical development by Innate Pharma and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - IPH-6501 in Mantle Cell Lymphoma

Data Insights

IPH-6501 by Innate Pharma for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

IPH-6501 is under clinical development by Innate Pharma and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - IPH-6501 in Diffuse Large B-Cell Lymphoma

Data Insights

IPH-6501 by Innate Pharma for Splenic Marginal Zone B-Cell Lymphoma: Likelihood of Approval

IPH-6501 is under clinical development by Innate Pharma and currently in Phase II for Splenic Marginal Zone B-Cell Lymphoma. According...

Likelihood of Approval and Phase Transition Success Rate Model - IPH-6501 in Splenic Marginal Zone B-Cell Lymphoma

Data Insights

IPH-6501 by Innate Pharma for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma): Likelihood of Approval

IPH-6501 is under clinical development by Innate Pharma and currently in Phase II for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated...

Likelihood of Approval and Phase Transition Success Rate Model - IPH-6501 in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma)

Data Insights

IPH-6501 by Innate Pharma for Nodal Marginal Zone B-Cell Lymphoma: Likelihood of Approval

IPH-6501 is under clinical development by Innate Pharma and currently in Phase II for Nodal Marginal Zone B-Cell Lymphoma. According...

Likelihood of Approval and Phase Transition Success Rate Model - IPH-6501 in Nodal Marginal Zone B-Cell Lymphoma

Data Insights

IPH-6501 by Innate Pharma for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval

IPH-6501 is under clinical development by Innate Pharma and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - IPH-6501 in Primary Mediastinal B-Cell Lymphoma